Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Consumer Discretionary Select Sector SPDR Fund trades at $115.97. Which is the better fit depends on your goals.
| BIO | XLY | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | — |
52-Week High | $339.75 | $124.52 |
52-Week Low | $241.71 | $105.64 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
XLY trades at $116.04, down 1.02% today amid a bearish technical signal with selling pressure outweighing buys 12 to 4. Analyst consensus is unanimously bullish with a 100% buy rating. Recent news highlights consumer discretionary as a potential sleeper opportunity for Q3 2026, though inflation and weak consumer sentiment pose headwinds. The stock shows neutral oscillators but bearish moving averages, with support at $114 and resistance at $118.
The outlook for XLY is cautiously optimistic given strong analyst support, but risks include persistent inflation eroding discretionary spending and technical weakness. Investment opportunity hinges on a consumer spending rebound, while key risks are macroeconomic pressures and sector underperformance. The dividend scheduled for June 2026 offers minor income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
